On June 10, 2026, the FDA approved new labeling for the OTC weight-loss drug alli (orlistat 60 mg) warning about rare but serious kidney injury and kidney stones. The warning also aligns across FDA-approved orlistat products, including prescription Xenical. If you have kidney disease or a history of kidney stones, ask a clinician before using orlistat—and know the symptom checklist that should trigger prompt medical evaluation.
On June 10, 2026, the FDA updated the OTC label for alli (orlistat 60 mg) with rare warnings about acute kidney injury and kidney stones. Patients taking prescription orlistat (Xenical) can use the same symptom checklist—but should confirm suitability with their clinician.
On June 10, 2026, FDA approved updates to the OTC weight-loss drug alli (orlistat 60 mg) label to highlight a rare risk of acute kidney injury and kidney stones. The label advises people who have ever had kidney disease or kidney stones to ask a health care provider first, and to stop using alli and contact a doctor if specific kidney-related symptoms appear.
The Medicare GLP-1 Bridge began July 1, 2026, but eligibility is limited and rule-based. Here’s how the $50 monthly copay works, which products are included, who may be excluded, and what to check before asking for a prescription.
FDA’s June 16, 2026 warning-letter wave aimed at telehealth marketing adds a practical question for patients: how do you tell a legitimate compounded GLP-1 prescription from a risky online pitch? Here is what FDA says to check before you pay or use the drug. ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters))
Not automatically, but FDA’s April 30, 2026 action was a proposal about one compounding pathway, not a same-day nationwide ban on every refill. Here’s what changed, what may still be possible, and what patients should ask before their next prescription is filled.
FDA says Tazverik is being withdrawn from the U.S. market after new safety data showed a higher-than-expected rate of new blood cancers. Here is what patients and families should do next.
Sun Pharmaceutical Industries is recalling one batch of doxorubicin hydrochloride liposome injection in the United States after the FDA said some vials may contain glass particles. Patients, caregivers, hospitals, infusion centers, and pharmacists should check lot numbers and contact the care team if the product may have been used.
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from a list that helps some large compounding facilities legally make GLP-1 drugs from bulk ingredients. The agency says it did not find a clinical need for that pathway, and it is asking for public comments through June 29, 2026. For patients who rely on compounded GLP-1 medicines, the change could affect access, pricing, and refill planning—but it is not final yet.
The FDA posted two hospital-level recalls of injectable products in late April and mid-May 2026. One involved doxorubicin liposome injection with possible glass particles; the other involved Lactated Ringer’s Injection with particulate matter. The notices matter most for hospitals, pharmacies, and infusion teams, but patients can ask whether any planned treatment is affected.
The FDA has added neurosurgical patties to its medical device shortage list, a sign that some hospitals may need to conserve supplies and plan around limited availability. At the same time, the agency posted a nationwide recall of one Sun Pharma doxorubicin product lot because of possible glass particles in some vials.
FDA is narrowing the path for compounded GLP-1 prescriptions as national supply stabilizes. Patients using these medicines should check whether their product is FDA-approved, compounded, or made from a bulk substance, because the rules and safety concerns are not the same.
Not automatically. FDA’s March and April 2026 actions say adding B12 or using telehealth does not by itself keep compounded semaglutide available or appropriate. What matters is the prescription, the pharmacy pathway, and whether a prescriber documented a real patient-specific need.
FDA approved Icotyde on March 17, 2026, giving some adults and teens with moderate to severe plaque psoriasis a new once-daily pill option.
The FDA approved daily obesity pill orforglipron on April 1. Here is what its main placebo-controlled trial found, and what patients still do not know.
A new trial found less clinically important bleeding with apixaban than rivaroxaban after a serious clot, but treatment changes still need a clinician.
Dry mouth is more than a nuisance. Many common medicines can reduce saliva, which can raise cavity risk and make it harder to protect teeth.
Current U.S. pain guidance says arthritis care should usually start with non-opioid options, with treatment tailored to arthritis type and daily function.
Federal telehealth prescribing flexibility for ADHD stimulants continues through December 31, 2026. Here’s what changed, what did not, and where barriers remain.
With semaglutide and tirzepatide shortages resolved, the FDA is tightening scrutiny of mass-marketed compounded GLP-1s. Here is what changed and what patients should ask now.
The short answer is not yet. Medicare has selected Ozempic, Rybelsus, and Wegovy for drug price negotiation, but the negotiated Medicare price is not scheduled to begin until January 1, 2027. Here is what changed in 2026, why the timeline is confusing, and why your own costs can still vary by plan.
The FDA has approved the first generic of Flovent HFA, but this is not a simple fix for every family affected by the brand-name inhaler’s discontinuation. Here’s what changed, who it may help, and why coverage and pharmacy access may still be uneven.
End of content
End of content
